-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Xeris Biopharma Holdings, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q2 2024.
- Xeris Biopharma Holdings, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$8.19M, a 48.8% increase year-over-year.
- Xeris Biopharma Holdings, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$37.2M, a 41.2% increase year-over-year.
- Xeris Biopharma Holdings, Inc. annual Operating Income (Loss) for 2023 was -$44M, a 46.3% increase from 2022.
- Xeris Biopharma Holdings, Inc. annual Operating Income (Loss) for 2022 was -$81.9M, a 28.8% increase from 2021.
- Xeris Biopharma Holdings, Inc. annual Operating Income (Loss) for 2021 was -$115M, a 37.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)